Data from the Swiss has also suggested that pre-treatment NLR was associated with shorter OS and PFS and with lower response rate in patients with metastatic NSCLC treated with nivolumab14.Our analyses revealed that, patients with pretreatment NLR>2.3 and PD-L1 expression had significantly shorter DFS and OS, suggesting a possible benefit population with immune checkpoint inhibitors. Here, CD274 is linked to non-small cell lung carcinoma.